Latest Insider Transactions at Nu Skin Enterprises, Inc. (NUS)
This section provides a real-time view of insider transactions for Nu Skin Enterprises, Inc. (NUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NU SKIN ENTERPRISES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NU SKIN ENTERPRISES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2022
|
Laura Nathanson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,179
+20.76%
|
-
|
|
Jun 02
2022
|
Pisano R. Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,179
+5.32%
|
-
|
|
Jun 02
2022
|
Zheqing Shen Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,179
+15.27%
|
-
|
|
Jun 02
2022
|
Edwina D Woodbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,179
+16.02%
|
-
|
|
Jun 02
2022
|
Emma S. Battle Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,179
+36.02%
|
-
|
|
Jun 02
2022
|
Daniel W Campbell Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,179
+17.79%
|
-
|
|
Jun 01
2022
|
Joseph Y Chang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,000
-23.23%
|
$736,000
$46.61 P/Share
|
|
Jun 01
2022
|
Joseph Y Chang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+29.11%
|
$480,000
$30.63 P/Share
|
|
May 25
2022
|
Ryan S Napierski President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-8.82%
|
$1,100,000
$44.84 P/Share
|
|
May 25
2022
|
Ryan S Napierski President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+8.13%
|
$850,000
$34.11 P/Share
|
|
May 23
2022
|
Andrew D Lipman Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.4%
|
$44,000
$44.95 P/Share
|
|
May 18
2022
|
Steven Lund Exec. Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
925
-0.51%
|
$42,550
$46.07 P/Share
|
|
May 16
2022
|
Steven Lund Exec. Chairman of the Board |
SELL
Open market or private sale
|
Indirect |
21,200
-10.52%
|
$954,000
$45.25 P/Share
|
|
May 13
2022
|
Steven Lund Exec. Chairman of the Board |
SELL
Bona fide gift
|
Indirect |
14,935
-6.9%
|
-
|
|
Apr 22
2022
|
Andrew D Lipman Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.38%
|
$47,000
$47.72 P/Share
|
|
Apr 21
2022
|
Connie Mang Yee Tang Chief Global Growth Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-3.41%
|
$52,640
$47.5 P/Share
|
|
Apr 21
2022
|
Connie Mang Yee Tang Chief Global Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,264
+13.83%
|
-
|
|
Mar 22
2022
|
Andrew D Lipman Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.37%
|
$47,000
$47.4 P/Share
|
|
Mar 09
2022
|
Edwina D Woodbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.09%
|
$564
$47.9 P/Share
|
|
Mar 02
2022
|
Joseph Y Chang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,423
-6.67%
|
$157,458
$46.2 P/Share
|
|
Mar 02
2022
|
Joseph Y Chang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,423
+11.49%
|
$102,690
$30.63 P/Share
|
|
Mar 01
2022
|
Joseph Y Chang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
28,577
-28.08%
|
$1,285,965
$45.63 P/Share
|
|
Mar 01
2022
|
Joseph Y Chang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,577
+35.67%
|
$857,310
$30.63 P/Share
|
|
Feb 25
2022
|
Ryan S Napierski President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-8.8%
|
$1,175,000
$47.49 P/Share
|
|
Feb 25
2022
|
Ryan S Napierski President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.88%
|
$850,000
$34.11 P/Share
|
|
Feb 25
2022
|
Ryan S Napierski President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,613
+20.49%
|
-
|
|
Feb 25
2022
|
Connie Mang Yee Tang Chief Global Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,147
+24.93%
|
-
|
|
Feb 25
2022
|
Mark H Lawrence Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,381
+17.38%
|
-
|
|
Feb 25
2022
|
Joseph Y Chang Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,744
+22.71%
|
-
|
|
Feb 25
2022
|
Chayce David Clark EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,430
+26.37%
|
-
|
|
Feb 25
2022
|
Steven Keith Hatchett Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,901
+9.63%
|
-
|
|
Feb 25
2022
|
James D Thomas Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,557
+37.4%
|
-
|
|
Feb 22
2022
|
Andrew D Lipman Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.35%
|
$53,000
$53.27 P/Share
|
|
Feb 15
2022
|
Ryan S Napierski President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,498
-4.71%
|
$220,402
$49.65 P/Share
|
|
Feb 15
2022
|
Mark H Lawrence Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,139
-10.74%
|
$251,811
$49.65 P/Share
|
|
Feb 15
2022
|
Joseph Y Chang Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,729
-9.64%
|
$84,721
$49.65 P/Share
|
|
Feb 15
2022
|
Chayce David Clark EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
865
-5.41%
|
$42,385
$49.65 P/Share
|
|
Feb 15
2022
|
James D Thomas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-12.17%
|
$39,151
$49.65 P/Share
|
|
Feb 15
2022
|
Steven Keith Hatchett Chief Product Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,021
-2.02%
|
$50,029
$49.65 P/Share
|
|
Jan 24
2022
|
Andrew D Lipman Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.33%
|
$50,000
$50.5 P/Share
|
|
Dec 08
2021
|
Edwina D Woodbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.09%
|
$552
$46.19 P/Share
|
|
Oct 05
2021
|
Jeffrey Clark Bettinger SVP, People and Places Officer |
SELL
Open market or private sale
|
Direct |
1,625
-9.18%
|
$66,625
$41.1 P/Share
|
|
Oct 01
2021
|
Jeffrey Clark Bettinger SVP, People and Places Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,498
-7.81%
|
$61,418
$41.48 P/Share
|
|
Sep 13
2021
|
Joseph Y Chang Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,000
-47.14%
|
$752,000
$47.41 P/Share
|
|
Sep 13
2021
|
Joseph Y Chang Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+32.04%
|
$480,000
$30.63 P/Share
|
|
Sep 08
2021
|
Edwina D Woodbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
11
+0.08%
|
$539
$49.54 P/Share
|
|
Sep 01
2021
|
Ryan S Napierski President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
13,707
+12.54%
|
-
|
|
Aug 01
2021
|
Chayce David Clark EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
1,863
+10.44%
|
-
|
|
Jul 02
2021
|
D Matthew Dorny General Counsel |
SELL
Open market or private sale
|
Direct |
6,200
-5.83%
|
$353,400
$57.08 P/Share
|
|
Jul 02
2021
|
D Matthew Dorny General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,200
+10.41%
|
$186,000
$30.63 P/Share
|